Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: From potential peptide vaccines to antibody immunotherapy

Immunology and Cell Biology

Volumn 87, Issue 5, 2009, Pages 391-399

  Pandey, Manisha ^a   Sekuloski, Silvana ^a   Batzloff, Michael R ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Group A streptococcus; Immunotherapy; Streptococcus pyogenes; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; CHICKENPOX ANTIBODY; CHOLERA TOXIN B SUBUNIT; DIPHTHERIA TOXOID; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; M PROTEIN; PEPTIDE VACCINE; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; RABIES IMMUNOGLOBULIN; SALIVARICIN A2; SALIVARICIN B; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ANTIBODY TITER; BACTERIAL COLONIZATION; CARBOXY TERMINAL SEQUENCE; CHICKENPOX; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MEGADOSE; GROUP A STREPTOCOCCAL INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOTHERAPY; LACTOBACILLUS DELBRUECKII; MEASLES; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN STRUCTURE; RABIES; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SALIVARIUS; TETANUS; TOXIC SHOCK SYNDROME;

HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MICROSCOPY, ELECTRON; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT;

STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 68149176712     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.29     Document Type: Review

References (117)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13: 470-511.
2. Bisno AL. Acute pharyngitis. NEnglJ Med 2001; 344:205-211.
3. Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles-report of a national institute of allergy and infectious diseases workshop. Clin Infect Dis 2005; 41: 1150-1156.
4. Komaroff AL, Pass TM, Aronson MD, Ervin CT, Cretin S, Winickoff RN et al. The prediction of streptococcal pharyngitis in adults. J Gen Intern Med 1986; 1:1-7.
5. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. AdvData 2002; 328:1-32.
6. Carapetis J. A review of WHO activities. In: The Burden of, and the Evidence for Strategies to Control Group A Streptococcal Diseases: Part3-The Current Evidence for the Burden of Group A Streptococcal Diseases. World Health Organization: Geneva, 2004, pp 1-49.
7. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-694.
8. Steer AC, Carapetis JR, Nolan TM, Shann F. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 2002; 38: 229-234.
9. CarapetisJR, WolffDR, CurrieBJ. Acuterheumaticfever and rheumatic heartdisease in the top end of Australia's Northern Territory. Med J Aust 1996; 164: 146-149.
10. World Health Organization. World Health Report. Office of Publications, World Health Organization: Geneva, 2000, 164-169.
11. Aziz RK, Kotb M. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. EmerglnfectDis 2008; 14: 1511-1517.
12. Cunningham MW. Pathogenesis of group A streptococcal infections and their sequelae. Adv Exp Med Biol 2008; 609:29-42.
13. Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalen C. The epidemiology of severeStreptococcuspyogenesassociated diseasein Europe. EuroSurveill2005; 10: 179-184.
14. Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein c5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005; 73: 7878-7886.
15. McMillan DJ, Batzloff MR, Browning CL, Davies MR, Good MF, Sriprakash KS et al. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004; 22: 2783-2790.
16. Terao Y, Okamoto S, Kataoka K, Hamada S, Kawabata S. Protective immunity against Streptococcus pyogenes challenge in mice after immunization with fibronectin- binding protein. JInfectDis2005; 192: 2081-2091.
17. Ulrich RG. Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J Immune Based Ther Vaccines 2008; 6:8.
18. Sabharwal H, Michon F, Nelson D, Dong W, Fuchs K, Manjarrez RC et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. JInfectDis2006; 193: 129-135.
19. ZabriskieJB, Poon-KingT, Blake MS, Michon F, Yoshinaga M. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp MedBiol1997; 418: 917-919.
20. Zagursky RJ, Anderson AS. Application of genomics in bacterial vaccine discovery: a decade in review. Curr Opin Pharmacol 2008; 8: 632-638.
21. Barinov A, Loux V, Hammani A, Nicolas P, Langella P, Ehrlich D et al. Prediction of surface exposed proteins in Streptococcus pyogenes, with a potential application to other Gram-positive bacteria. Proteomics2009; 9:61-73.
22. Fischetti VA, Jones KF, Hollingshead SK, Scott JR. Structure, function, and genetics of streptococcal M protein. Rev Infect Dis1988; 10 (Suppl 2): S356-S359.
23. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70: 2171-2177.
24. KotloffKL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC et al. Safetyandimmunogenicityofarecombinantmultivalentgroupastreptococcal vaccinein healthy adults: phase 1 trial. JAMA 2004; 292:709-715.
25. Mannam P, Jones KF, Geller BL. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004; 72: 3444-3450.
26. Bessen D, Fischetti VA. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization bygroup A streptococci. Infect Immun 1988; 56: 2666-2672.
27. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997; 9: 1723-1733.
28. Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group A streptococcal M- protein vaccine. JImmunol1993; 151: 2188-2194.
29. Beachey EH, Seyer JM. Protective and nonprotective epitopes of chemically synthesized peptides of the NH2 terminal region of type 6 streptococcal -M protein. JImmunol 1986; 136: 2287-2292.
30. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005; 12: 833-836.
31. McNeil SA, Halperin SA, LangleyJM, Smith B, Warren A, SharrattGP et al. Safetyand immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis2005; 41: 1114-1122.
32. Bessen D, Fischetti VA. Passive acquired mucosal immunity to group A streptococci bysecretoryimmunoglobulin A. JExpMed1988; 167: 1945-1950.
33. BrandtzaegP. Roleofsecretoryantibodiesin thedefenceagainstinfections. IntJMed Microbiol 2003; 293:3-15.
34. Brandt ER, Hayman WA, Currie B, Carapetis J, Wood Y, Jackson DC et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology1996; 89: 331-337.
35. Pruksakorn S, Galbraith A, Houghten RA, GoodMF. ConservedTandB cell epitopeson theM protein ofgroupAstreptococci. Induction ofbactericidal antibodies. JImmunol 1992; 149: 2729-2735.
36. Batzloff M, Yan H, Davies M, Hartas J, Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian JMedRes 2004; 119 (Suppl): 104-107.
37. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER et al.Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187: 1598-1608.
38. D'Alessandri R, Plotkin G, Kluge RM, Wittner MK, Fox EN, Dorfman A et al. Protective studieswith groupAstreptococcal M protein vaccine. III. Challengeofvolunteersafter systemic or intranasal immunization with type 3 or type 12 group A Streptococcus. JInfectDis1978; 138: 712-718.
39. Brandt ER, Hayman WA, Currie B, Carapetis J, Jackson DC, Do KA et al. Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian aboriginal endemic communities. Int Immunol 1999; 11 : 569-576.
40. BrandtER, Teh T, RelfWA, Hobb RI, Good MF. Protectiveand nonprotectiveepitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 2000; 68: 6587-6594.
41. Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian aboriginal population. Nat Med2000; 6: 455-459.
42. Jackson DC, O'Brien Simpson N, Ede NJ, Brown LE. Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 1997; 15: 1697-1705.
43. Kreutz M, Ackermann U, Hauschildt S, Krause SW, Riedel D, Bessler W et al. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccocus aureus in human monocytes. Immunology1997; 92:396-401.
44. MelchersF, Braun V, GalanosC. Thelipoprotein oftheouter membraneofEscherichia coli: a B-lymphocyte mitogen. JExpMed1975; 142: 473-482.
45. Wiesmuller KH, Bessler W, Jung G. Synthesis of the mitogenic S-[2,3-bis(palmitoy- loxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe- Seyler's Zeitschrift Fur Physiologische Chemie 1983; 364: 593-606.
46. Hoffmann P, HeinleS, SchadeUF, LoppnowH, Ulmer AJ, Flad HD et al. Stimulation of human and murine adherent cells bybacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology1988; 177: 158-170.
47. Seifert R, Schultz G, Richter-Freund M, Metzger J, Wiesmuller KH, Jung G et al. Activation of superoxide formation and lysozyme release in human neutrophils bythe synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-bind- ing proteins and synergism with chemotactic peptides. Biochem J 1990; 267: 795-802.
48. BergM, OffermannsS, SeifertR, SchultzG. SyntheticlipopeptidePam3CysSer(Lys)4 is an effective activator of human platelets. Am J Physiol Cell Physiol 1994; 266: C1684-C1691.
49. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. JImmunol 2002; 169: 4905-4912.
50. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. JInfectDis2006; 194: 325-330.
51. OliveC, Batzloff MR, Toth I. Lipid corepeptidetechnologyand group Astreptococcal vaccine delivery. Expert Rev Vaccines 2004; 3:43-58.
52. McGeary RP, Olive C, Toth I. Lipid and carbohydrate based adjuvant/carriers in immunology. JPept Sci 2003; 9: 405-418.
53. Olive C, Toth I, Jackson D. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini RevMedChem2001; 1: 429-438.
54. Wong A, Toth I. Lipid, sugar and liposaccharide based delivery systems. Curr Med Chem 2001; 8: 1123-1136.
55. Hayman WA, Toth I, Flinn N, Scanlon M, Good MF. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 2002; 80: 178-187.
56. Olive C, Batzloff MR, Horvath A, Wong A, Clair T, Yarwood P et al. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 2002; 70: 2734-2738.
57. OliveC, Batzloff M, Horvath A, Clair T, Yarwood P, Toth I et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003; 71: 2373-2383.
58. OliveC, Hsien K, Horvath A, ClairT, YarwoodP, Toth I et al. Protection againstgroup A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005; 23: 2298-2303.
59. Fujita Y, Abdel-Aal AB, Wimmer N, Batzloff MR, Good MF, Toth I. Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. BioorgMedChem2008; 16: 8907-8913.
60. Simerska P, Abdel-Aal AB, Fujita Y, Batzloff MR, Good MF, Toth I. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. Biopoly- mers2008; 90: 611-616.
61. Simerska P, Abdel-Aal AB, Fujita Y, Moyle PM, McGeary RP, Batzloff MR et al. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. JMedChem 2008; 51: 1447-1452.
62. Costalonga M, ClearyPP, Fischer LA, Zhao Z. Intranasal bacteria induceTh1 but not Treg or Th2. Mucosal Immunol 2009; 2:85-95.
63. van't Hof W, Veerman EC, Helmerhorst EJ, Amerongen AV. Antimicrobial peptides: properties and applicability. Biol Chem 2001; 382:597-619.
64. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends Biotechnol 2003; 21:217-223.
65. Grahn E, Holm SE. Bacterial interference in the throat flora during a Streptococcal tonsillitis outbreak in an apartment house area. Zentralbl Bakteriol Mikrobiol Hyg 1983; 256:72-79.
66. Sanders E. Bacterial interference. I. Its occurrence among the respiratory tract flora and characterization of inhibition of group A streptococci by viridans streptococci. JInfectDis1969; 120:698-707.
67. SandersCC, SandersWEJ. Enocin: an antibioticproduced byStreptococcussalivarius that may contribute to protection against infections due to group A streptococci. JInfectDis1982; 146: 683-690.
68. Dempster RP, Tagg JR. The production of bacteriocin-link substances by the oral bacterium Streptococcussalivarius. Arch Oral Biol 1982; 27: 151-157.
69. Ross KF, Ronson CW, Tagg JR. Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl Environ Microbiol 1993; 59: 2014-2021.
70. Wescombe PA, Upton M, Dierksen KP, Ragland NL, Sivabalan S, Wirawan RE et al. Production ofthelantibiotic salivaricin Aand itsvariants byoral streptococci anduse of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol 2006; 72: 1459-1466.
71. Pirofsky B, Kinzey DM. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases. Drugs 1992; 43:6-14.
72. Mascini EM, JanszeM, SchoulsLM, VerhoefJ, Van DijkH. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int JAntimicrobAgents2001; 18:395-398.
73. BasmaH, Norrby-Teglund A, McGeer A, LowDE, El-AhmedyO, DaleJB et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections. Infect Immun 1998; 66: 2279-2283.
74. Casadevall A, Scharff MD. Return to thepast: thecasefor antibody-based therapiesin infectious-diseases. Clin InfectDis1995; 21: 150-161.
75. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 1996; 2: 200-208.
76. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38: 1695-1702.
77. Rackemann FM. Allergy serum reactions, with particular reference to the prevention and treatment of tetanus. NEnglJMed1942; 226: 726-733.
78. Pepper DS, Flippin HF, SchwartzL, Lockwood JS. Theresultsofsulfapyridinetherapy in 400 cases of typed pneumococcic pneumonia. AmJMedSci1939; 198:22-35.
79. Bussel JB, Cunninghamrundles C. Intravenous usage of gamma-globulin- humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications. Cancer Invest 1985; 3: 361-366.
80. Mofenson LM, Moye J, Korelitz J, Bethel J, Hirschhorn R, Nugent R. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial-infections and reduction of hospitalizations in human-immunodeficiency virus-infected children. PediatrInfect DisJ1994; 13: 477-484.
81. Yap PL. Does intravenous immune globulin have a role in HIV-infected patients. Clin Exp Immunol 1994; 97:59-67.
82. Talkington DF, SchwartzB, BlackCM, ToddJK, ElliottJ, BreimanRF et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun 1993; 61 : 3369-3374.
83. Lemley PV, Amanatides P, Wright DC. Identification and characterization of a monoclonal-antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 1994; 13: 417-421.
84. GoyacheJ, Orden JA, Blanco JL, Hernandez J, Domeenech A, Su-rez G et al. Murine monoclonal antibodies against staphylococcal enterotoxin B: production and characterization. FEMS Microbiol Lett 1992; 89: 246-254.
85. Feldmesser M, Kress Y, Novikoff P, Casadevall A. Cryptococcus neoformans is a facultativeintracellular pathogen in murinepulmonaryinfection. InfectImmun2000; 68: 4225-4237.
86. Miles SA, Conrad SM, Aves RG, Jeronimo SMB, Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. JExpMed 2005; 201: 747-754.
87. Madaio MP, Yanase K, Foster MH, Smith RM, Emmons TK, Fabbi M et al. Nuclear localization of autoantibodies. Novel insights into protein translocation and cellular function. B Lymphocytes Autoimmunity 1997; 815: 263-266.
88. Avrameas A, Ternynck T, Nato F, Buttin G, Avrameas S. Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules. Proc Natl Acad Sci USA 1998; 95: 5601-5606.
89. Yanase K, Smith RM, Jarett L, Madaio MP Intracellular trafficking of anti-DNA antibody in caveoli with myosin 1 en route to the nucleus. Mol Biol Cell 1997; 8: 429A.
90. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
91. Siegert J, Sastalla I, Chhatwal GS, Medina E. Vaccination equally enables both genetically susceptible and resistant mice to control infection with group A streptococci. Microbes Infect 2006; 8:347-353.
92. Olive C, Clair T, Yarwood P, Good MR. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002; 20: 2816-2825.
93. Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi K, Totsuka K et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001; 69:924-930.
94. Liu MY, Zhu H, Zhang JL, Lei BF. Active and passive immunizations with the Streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect Immun 2007; 75: 3651-3657.
95. Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One 2009; 4:e5147.
96. Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005; 73: 7878-7886.
97. Purushothaman SS, Park HS, Cleary PP. Promotion of fibronectin independent invasion by C5a peptidase into epithelial cells in group A streptococcus. Indian J MedRes2004; 119:44-47.
98. Beachey EH, Stollerman GH, Johnson RH, Bisno AL, Ofek I. Immunogenecity in animals and man of a structurally defined polypeptide of streptococcal M24 protien I. Clin Res1979; 27: A514.
99. Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine1997; 15: 1805-1812.
100. Cunningham MW, Russell SM. Study of the heart reactive antibody in antisera and hybridoma culture fluids against group A streptococci. Infect Immun 1983; 42: 531-538.
101. Cunningham MW, Krisher K, Graves DC. Murine monoclonal-antibodies reactive with human-heart and group A streptococcal membrane antigen. Infect Immun 1984; 46: 34-41.
102. Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S et al. Group a streptococcal bacteremia: The role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996; 173:619-626.
103. MehtaS, McGeerA, LowDE, HallettD, BowmanDJ, Grossman SL et al. Morbidityand mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 2006; 130: 1679-1686.
104. Norrby-Teglund A, Stevens DL. Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Curr Opin Infect Dis1998; 11: 285-291.
105. Fischetti VA. Streptococcal M-protein. Sci Am 1991; 264:58-65.
106. Basma H, Norrby-Teglund A, Guedez Y, McGeer A, LowDE, El-AhmedyO et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 1999; 67: 1871-1877.
107. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. JInfectDis1992; 166: 31-37.
108. Norrby-Teglund A, Pauksens K, Holm SE, Norgren M. Relation between lowcapacity ofhuman sera toinhibitstreptococcal mitogens and seriousmanifestation ofdisease. J Infect Dis 1994; 170:585-591.
109. Norrby-TeglundA, Newton D, KotbM, Holm SE, Norgren M. Superantigenicproperties of the group A streptococcal exotoxin SPEF (MF). Infect Immun 1994; 62: 5227-5233.
110. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999; 28: 800-807.
111. Ferguson M, Cohen J, Sriskandan S. Evaluation of IVIG in HLA class II+ mice infected with Streptococcus pyogenes. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002; 42:57.
112. DarenbergJ, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al., StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-340.
113. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U et al. Evidence for the presence of streptococcal-superantigen- neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64: 5395-5398.
114. DarenbergJ, Soderquist B, Normark BH, Norrby-Teglund A. Differences in potencyof intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implicationsfor therapyoftoxicshock syndrome. ClinInfectDis2004; 38: 836-842.
115. SchrageB, Duan GW, YangLP, FraserJD, ProftT. Differentpreparationsofintravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006; 43: 743-746.
116. O'Grady KAF, Kelpie L, Andrews RM, Curtis N, Nolan TM, Selvaraj G et al. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med J Aust 2007; 186: 565-569.
117. Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 2001; 8: 859-863